Biocon Biologics Acquires Pfizer’s Research Facility to Expand its Research and Development Footprint

 Biocon Biologics Acquires Pfizer’s Research Facility to Expand its Research and Development Footprint

Biocon Biologics Acquires Pfizer’s Research Facility to Expand its R&D Footprints

Shots:

  • Biocon Biologics has acquired Pfizer’s 60,000 sq. ft state-of-the-art, bench to pilot scale R&D facility at TICEL Bio Park in Chennai, India
  • The focus of the acquisition is to expand Biocon’s R&D capabilities and to accelerate the development of its biosimilars from lab to pilot scale, addressing the needs of patients globally
  • The facility will house an early stage R&D center including pilot-scale R&D unit, equipped with cell line development, drug substance process development from bench scale to 400L scale bioreactors, drug product formulation laboratories, analytical R&D laboratories with 250+ scientists

Click here to­ read full press release/ article | Ref: Biocon | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post